What is the current Price Target for the HilleVax stock?

The average HilleVax target price is $2.17. This is 56.44% higher than the current stock price. The highest price target is 80.51%, the lowest is 44.40%. 3 Analysts have issued a price target HilleVax 2026 .

How high will the HilleVax stock rise?

No reliable answer can be given as to how high the HilleVax stock will rise. The performance of stocks, including the HilleVax stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the HilleVax stock today?

The performance of HilleVax stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the HilleVax stock fall?

The decline in HilleVax stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

HilleVax Forecast, price target & analysts

$1.50

8.30% today

NYSE, Apr 02, 09:51 pm CET

ISIN

US43157M1027

Symbol

HLVX

Reports

Quarter | Annual

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

HilleVax Target price 2025 - Analyst rating & recommendation

HilleVax Classifications & Recommendation:

Hold

100%

HilleVax Price Target

Target Price	$2.17
Price	$1.39
Potential	56.44% register free of charge
Number of Estimates	3

	3 Analysts have issued a price target HilleVax 2026 . The average HilleVax target price is $2.17. This is 56.44% register free of charge higher than the current stock price. The highest price target is $2.50 80.51% register free of charge , the lowest is $2.00 44.40% register free of charge .
	A rating was issued by 3 analysts: 0 Analysts recommend HilleVax to buy, 3 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the HilleVax stock has an average upside potential 2026 of 56.44% register free of charge . Most analysts recommend the HilleVax stock at Hold.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-3.00	-1.20
	1.32%	60.00%
P/E		negative

3 Analysts have issued a HilleVax forecast for earnings per share. The average HilleVax EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-3.00	1.32%
2025	$-1.20 60.00% Unlock
2026	$-1.04 13.33% Unlock
2027	$-1.07 2.88% Unlock
2028	$-0.75 29.91% Unlock
2029	$-0.58 22.67% Unlock

Current	-0.46	91.59%
2025	-1.15 150.00% Unlock
2026	-1.33 15.65% Unlock
2027	-1.29 3.01% Unlock
2028	-1.85 43.41% Unlock
2029	-2.40 29.73% Unlock

HilleVax...

Current HilleVax Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 31 2025

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 31 2025

Discover more stocks with a high price target

Coinbase Global, Inc. 81.87%

BioNTech SE - ADR 53.26%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now